Regulatory
HIGHTrigger: The quarter was impacted because customer approvals in Canada were delayed.
Monitor: regulatory
OneSource Specialty Pharma Ltd: Stock Analysis & Fundamentals
Updated this weekOneSource Specialty Pharma Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. ROE: -1.1%. This stock is not currently in the Nifty 500 momentum outperformers list.
OneSource Specialty Pharma Ltd Key Facts
What's Happening
💪Debt reduced 14% YoY — balance sheet strengthening
👔Promoter stake down 0.7% this quarter
🌐FII stake increased 1.9% this quarter
🏛️DII reducing — stake down 2.1%
Key Risks
1. Regulatory
HIGH2. Logistics
MEDIUMKey Numbers
Current Price
₹1,564
Market Cap
17.9K Cr
Valuation
N/AWhat Are the Key Risks for OneSource Specialty Pharma Ltd?
Earnings deceleration risks from management commentary
Logistics
MEDIUMTrigger: Management said constrained supply has to ease as more markets open and capacity is added.
Monitor: logistics
What Is OneSource Specialty Pharma Ltd's Management Saying?
Key quotes from recent conference calls
“This has since been deferred, as they had received certain requests for additional information from the regulatory agency. [Risk (regulatory): HIGH]”
“the supply chain overall continue to remain constrained, whether it is in API's or in cartridges or in devices. [Risk (logistics): MEDIUM]”
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: OneSource Specialty Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were OneSource Specialty Pharma Ltd's latest quarterly results?
OneSource Specialty Pharma Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: -95.3%
- Revenue Growth YoY: +0.5%
- Operating Margin: 21.5%
What is OneSource Specialty Pharma Ltd's price-to-book ratio?
OneSource Specialty Pharma Ltd's price-to-book ratio is 3.1x.
- Price-to-Book (P/B): 3.1x
- Book Value per Share: ₹509
- Current Price: ₹1564
Is OneSource Specialty Pharma Ltd a fundamentally strong company?
OneSource Specialty Pharma Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 1.0%
Is OneSource Specialty Pharma Ltd debt free?
OneSource Specialty Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹2,000 Cr
What is OneSource Specialty Pharma Ltd's return on equity (ROE) and ROCE?
OneSource Specialty Pharma Ltd's return ratios over recent years
- FY2024: ROCE -12.0%
- FY2025: ROCE 6.0%
- FY2026: ROCE 1.0%
Is OneSource Specialty Pharma Ltd's cash flow positive?
OneSource Specialty Pharma Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹9 Cr
- Free Cash Flow (FCF): ₹-486 Cr
What is OneSource Specialty Pharma Ltd's dividend yield?
OneSource Specialty Pharma Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹1564
Who holds OneSource Specialty Pharma Ltd shares — promoters, FII, DII?
OneSource Specialty Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 30.5%
- FII (Foreign): 17.5%
- DII (Domestic): 20.6%
- Public: 31.4%
Is promoter holding increasing or decreasing in OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd's promoter holding has increased recently.
- Current Promoter Holding: 30.5% (Mar 2026)
- Previous Quarter: 29.9% (Dec 2025)
- Change: +0.55% (increasing — positive signal)
Is OneSource Specialty Pharma Ltd a new momentum entry or an established outperformer?
OneSource Specialty Pharma Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
What are the key risks in OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd has 2 key risks worth monitoring
- [HIGH] Regulatory — The quarter was impacted because customer approvals in Canada were delayed.
- [MEDIUM] Logistics — Management said constrained supply has to ease as more markets open and capacity is added.
What did OneSource Specialty Pharma Ltd's management say in the latest earnings call?
In Q3 FY26, OneSource Specialty Pharma Ltd's management highlighted
- "This has since been deferred, as they had received certain requests for additional information from the regulatory agency. [Risk (regulatory): HIGH]"
- "the supply chain overall continue to remain constrained, whether it is in API's or in cartridges or in devices. [Risk (logistics): MEDIUM]"
Is OneSource Specialty Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why OneSource Specialty Pharma Ltd may be worth studying
- Cash flow is positive — CFO ₹9 Cr
What is the investment thesis for OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd investment thesis summary:
Risk Factors (Bear Case)
- Key risk: Regulatory
What is the future outlook for OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd's forward outlook based on current data signals
- Key Risk: Regulatory
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.